FTEAA

FTEAA is a 4-styrylpiperidine inhibitor. FTEAA exhibits potent inhibitory effect towards both monoamine oxidase with IC50s of 0.52 μM (MAO-A), 1.02 μM (MAO-B), respectively. MAO inhibitors can be used for cardiovascular, neurological and oncological disorders research[1][2].

Product Specifications

UNSPSC

12352005

Target

Monoamine Oxidase

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/fteaa.html

Solubility

10 mM in DMSO

Smiles

O=C(C1=C(NC2=CC=C(F)C=C2)CC(C3=CC=C(C(F)(F)F)C=C3)N(C4=CC=C(F)C=C4)C1C5=CC=C(C(F)(F)F)C=C5)OCC

Molecular Formula

C34H26F8N2O2

Molecular Weight

646.57

References & Citations

[1]Schwartz TL, et al. A neuroscientific update on monoamine oxidase and its inhibitors. CNS Spectr. 2013 Dec;18 Suppl 1:25-32; quiz 33. |[2]Bilal AK, et al. Exploring Highly Functionalized Tetrahydropyridine as a Dual Inhibitor of Monoamine Oxidase A and B: Synthesis, Structural Analysis, Single Crystal XRD, Supramolecular Assembly Exploration by Hirshfeld Surface Analysis, and Computational Studies. ACS Omega. 2022 Aug.